Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2021 Feb 19;65(6):2000945. doi: 10.1002/mnfr.202000945

Is There a Carcinogenic Risk Attached to Vitamin B12 Deficient Diets and What Should We Do About It? Reviewing the Facts

Alexandra K Loedin 1, Dave Speijer 1,
PMCID: PMC8126961  PMID: 33548097

Abstract

The number of individuals partaking in veganism has increased sharply in the last decade. Therefore, it is critical to look at the implications of vegan diets for public health. Although there are multiple health benefits of a vegan diet, studies have also linked the diet with deficiencies in various micronutrients. This study focuses on vitamin B12, because of its critical role in DNA synthesis and methylation. In light of these connections, a critical review of recent scientific literature is conducted to understand the effects of a B12 deficient diet on the genome and epigenome, and whether it can give rise to cancer. It is observed that a B12 deficiency leads to increased uracil misincorporation, leading to impaired DNA synthesis and genomic instability. The deficiency also leads to global hypomethylation of DNA, a hallmark of early carcinogenesis. The findings of this study highlight the need for increased awareness among vegans to ensure adequate B12 intake through supplementation or consumption of fortified products as a preventative measure. Additionally, the biofortification of staple crops and an improved version of fermented products with increased B12 content can be developed when inadequate intake seems otherwise inevitable.

Keywords: Cancer, DNA methylation, DNA synthesis, veganism, vitamin B12 deficiency


Percentages of those partaking in veganism are rising. Vegan diets can result in insufficient levels of vitamins, such as B12, critical for DNA synthesis and methylation. Scientific literature shows B12 deficient diets to influence the (epi)genome and thus increase cancer risk. We conclude that vegans should make sure of sufficient B12 intake.

graphic file with name MNFR-65-2000945-g001.jpg

1. Introduction

Although the concept of a plant‐based diet is not novel, recently an impressive rise in individuals adopting a vegan diet has been observed globally. Veganism is defined as the practice of not consuming animal‐derived products, such as meat, fish, poultry, eggs, dairy products, and honey.[ 1 ] Followers of the vegan diet are commonly referred to as “vegans” and this terminology will be used in this review. Taking the United States as an example, a recent study showed that 6% of the total population identified as followers of the vegan diet,[ 2 ] of which 11% are young adults (age 25–34).[ 3 ] Similarly, there was an increase of 45,0000 vegans in the United Kingdom in the last 5 years.[ 4 ] In Portugal, there were 12,0000 individuals who claimed to follow a plant‐based diet in 2018, compared to a mere 30,000 in 2007.[ 2 ] These statistics could be attributed to studies linking a vegan diet with improved health, sustainability, and reducing the global carbon footprint.[ 3 , 5 , 6 , 7 , 8 ] Despite its benefits, plant‐based diets tend to result in a deficiency of certain micronutrients, namely iron, zinc, calcium, vitamin D, omega‐3 (n‐3) fatty acids, iodine, and vitamin B12 (B12).[ 3 ]

This review will focus on B12, also known as cobalamin, an essential micronutrient that is present in meat, fish, egg, and dairy products.[ 9 , 10 ] B12 is produced by microorganisms that are present in the bowel of ruminants (e.g., cattle, sheep, etc.) and omnivorous animals (e.g., chicken, pigs). In aquatic environments such microorganisms are found in phytoplankton, which are consumed by fishes and crustaceans. Once absorbed in the small intestine, the vitamin is then stored in the liver and muscle of these animals or secreted into milk.[ 11 ] This water‐soluble vitamin acts as a co‐factor for methionine synthase (MS; the enzyme that catalyzes the conversion of homocysteine to methionine) and L‐methylmalonyl‐CoA mutase (the enzyme that catalyzes the conversion of methylmalonic acid (MMA) to succinyl‐CoA). Thus, B12 plays a crucial role in red blood cell production, neurologic development and function, DNA synthesis, and DNA methylation.[ 12 ] A B12 deficiency is correlated with both aberrant DNA synthesis and methylation.[ 13 ] Errors in these physiological processes lead to a variety of clinical manifestations, resulting in megaloblastic anemia, neurological impairment, cognitive decline, and neurodevelopmental disorders.[ 14 , 15 ] Therefore, it is imperative to have sufficient amounts of B12 in one's diet.

Multiple studies have shown that due to the dietary intake restrictions of a vegan diet, vegans have the highest risk of developing a B12 deficiency, in comparison to those consuming other vegetarian diets or omnivorous diets. In these studies, a B12 serum deficiency is defined as having less than 200 pmol L‐1 of B12.[ 16 , 17 ] In the United States, the prevalence of a B12 deficiency in young adults (age 20–39) was less than 3%; however, amongst vegans, the prevalence was a stunning 43%.[ 16 , 18 ] Furthermore, individuals who adopted a vegan diet at a younger age were found to have a higher risk of depleted B12 levels later in life.[ 16 ] Having a deficiency at a young age could take a few years to trigger the onset of clinical manifestations.[ 19 ] Previous research focused heavily on the effects of maternal B12 status on neonatal development.[ 20 , 21 , 22 ] However, concurrent with the rising percentage of vegans among the younger demographic, research focus has shifted to how a B12 deficiency affects adult health.[ 15 ]

Recent studies have indicated a possible link between a B12 deficiency and the onset of cancer.[ 23 , 24 ] In 2019, cancer was considered one of the leading causes of death in high‐income countries, with almost twice as many deaths as from cardiovascular diseases, the leading cause of death worldwide.[ 25 ] Despite the increasing amount of research, there is a substantial lack of systematic overviews regarding cancer as a potential clinical manifestation of a B12 deficiency. Therefore, this review aims to evaluate the effects of a B12 deficiency on both genome stability and the epigenome, providing a comprehensive overview of possible contributions to cancer development. We limited our sources to peer‐reviewed scientific papers, with the exception of online news articles from reputable websites for vegans (e.g., The Vegan Society).

The number of vegans, especially of the younger demographic, is predicted to further increase in the coming years due to the heightened awareness of the impact of non‐vegetarian, meat‐based diets on greenhouse gasses emissions, leading to climate change.[ 3 ] Hence, it is critical to build an in‐depth understanding of the metabolic implications of this global dietary trend on individual health. We should also recognize the need for appropriate prevention strategies to ensure adequate B12 intake, mitigating the potentially adverse effects on public health.

2. Vitamin B12

Though the vegan diet has benefits, it also has been linked to a deficiency of multiple essential micronutrients, B12 (see Figure  1 ) amongst them.[ 3 ] As described above, B12 is a water‐soluble vitamin found predominantly in animal derived dietary products. [ 14 ] B12 was first isolated in 1948 and later synthesized in 1973.[ 26 ] It is part of the corrinoid family, as its chemical structure includes a corrin ring. This ring is made up of four reduced pyrrole rings, which are linked together in a macrocyclic ring, coordinately linked to a central cobalt atom. The structure of the corrin ring appears similar to the structure of heme in hemoglobin, apart from one less methylene bridge and the cobalt atom at its center. Also linked to the cobalt atom is a 5,6,‐dimethylbenzimidazole nucleotide part of the molecule.[ 27 ] Four main active forms of B12 exist, cyanocobalamin, hydroxocobalamin, methylcobalamin (CH3•B12), and adenosylcobalamin; these differ in the “R” groups attached to the cobalt atom depicted in Figure 1. The three latter forms are typically found in animal products, while cyanocobalamin is the commercially available form used in supplements to prevent and treat a B12 deficiency.[ 28 ]

Figure 1.

Figure 1

Chemical structure of B12. The structure of the vitamin is centered around a corrin ring (highlighted in purple) coordinately linked to a center cobalt atom (highlighted in yellow). There are four forms of B12, each differing in the functional group (highlighted in green) attached to the center cobalt atom. The R group could either be an adenosine (adenosylcobalamin), a methyl (methylcobalamin), a hydroxyl (hydroxocobalamin), or a cyanide group (cyanocobalamin), as indicated. Based on Jägerstad and Arkbåge, 2003.[ 27 ]

2.1. B12 Absorption

In the human body, B12 is extracted and absorbed from food in a series of steps that involve a complex network of proteins. Upon dietary intake, gastric acid and pepsin in the stomach release B12 from the proteins it was previously bound to. The vitamin then proceeds to attach to haptocorrin (HC), a glycoprotein primarily secreted by the salivary gland, until it reaches the duodenum. In the duodenum, HC is digested by pancreatic proteases, in the process releasing B12. Once released, B12 binds to intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells. Binding to IF is essential for the absorption of B12 to occur, and an absence of IF leads to only 1–2% absorption of B12. Next, the vitamin is absorbed in the terminal ileum by IF receptors. [ 26 , 28 , 29 ] Once absorbed, B12 complexes with transcobalamin (TC) in the enterocyte, before release into the circulation (Figure  2 ). This complex allows B12 to be delivered to the tissues; 50% of B12 is taken up by the liver.[ 30 ] The body stores about 3–4 mg of B12 in the liver. This is a substantial amount and, if all dietary B12 uptake is discontinued, is sufficient for approximately 3 to 6 years before symptoms begin manifesting clinically. Thus, a B12 deficiency is relatively slow to develop.[ 31 ] However, upon bariatric surgery, symptoms are observed earlier (most likely by a combination of interrupting the enterohepatic cycle and presurgical reductions in food intake).

Figure 2.

Figure 2

Absorption of B12. B12 gets extracted from food in the stomach by gastric juices and pepsin. It then binds to HC. Once the B12‐HC complex reaches the duodenum, HC is degraded by pancreatic proteases, and B12 binds to IF. In the terminal ileum, the B12‐IF complex is absorbed by the IF receptors, causing B12 to be released from IF. In the enterocyte, B12 then complexes with TC and is released into the circulation. This complex allows B12 to be absorbed by the tissues, especially the liver. Based on Lieberman and Marks, 2017.[ 30 ]

2.2. The Role of B12

B12 is a fundamental nutrient, especially for two significant processes in the body, namely DNA synthesis and DNA methylation. Both processes form part of the one‐carbon metabolism pathway, a set of linked cyclical cytosolic reactions that result in the formation of methionine from homocysteine and donation of methyl groups. Methionine is crucial for the regeneration of S‐adenosylmethionine (SAM), the universal methyl donor; combining methionine with adenosine triphosphate (ATP) results in the “activated” SAM molecule. SAM is responsible for reactions that require the transfer of methyl groups to oxygen or nitrogen atoms of the acceptor molecule.[ 32 ] When SAM donates a methyl group, it consequently forms S‐adenosylhomocysteine (SAH), which can then be further hydrolyzed to form homocysteine and adenosine.[ 29 ] SAM is critical for the maintenance of methylation patterns in DNA.[ 33a,b ]

B12 works in unison with vitamin B9 (folate), vitamin B6, and vitamin B2 in the one‐carbon metabolism pathway. [ 13 , 34 ] All four B vitamins act as cofactors for enzymes which participate in the pathway. The coenzyme form of folate, tetrahydrofolate (THF), acts as the primary acceptor for one‐carbon groups. A methyl group from serine is transferred to THF in order to form 5,10‐methylenetetrahydrofolate (5,10‐MTHF). This process is catalyzed by serine hydroxymethyltransferase with vitamin B6 as a cofactor. 5,10‐MTHF can then be further utilized in the de novo formation of thymidine, the synthesis of purines, as well as in the re‐synthesis of methionine.[ 13 ] B12, in the form of CH3•B12, is a cofactor for the enzyme MS, the enzyme responsible for catalyzing the central reaction of the one‐carbon pathway. The steps are as follows: (1) a methyl group from 5‐methyltetrahydrofolate (5‐MTHF), the predominant form of dietary folate, is transferred to B12 to form CH3•B12; (2) this methyl group is then transferred to homocysteine by MS, resulting in the formation of methionine; (3) the remaining tetrahydrofolate (THF) can then be converted to 5,10‐MTHF, which can be further reduced by methylenetetrahydrofolate reductase (MTHFR), a vitamin B2 containing enzyme, to become 5‐MTHF (Figure  3 ).[ 13 , 15 , 26 , 28 ]

Figure 3.

Figure 3

The one‐carbon metabolism pathway. Serine donates a methyl group to THF to create 5,10‐MTHF, leaving glycine. This (reversible) reaction is catalyzed by serine hydroxymethyltransferase (SHMT), using vitamin B6 as a cofactor. 5,10‐MTHF is converted to 5‐MTHF by methylenetetrahydrofolate reductase (MTHFR), with vitamin B2 as a cofactor and NADPH as electron donor (not depicted). 5‐MTHF, which can also be acquired from dietary folate (B9), donates a methyl group to B12 to create CH3•B12, a cofactor for the enzyme methionine synthase (MS), which catalyzes the conversion of homocysteine to methionine, by in turn transferring this CH3 group. Methionine is combined with ATP to become SAM, which maintains methylation reactions. When SAM donates a methyl group, it becomes SAH, which can be further hydrolyzed to form homocysteine and adenosine (by S‐adenosylhomocysteine hydrolase; SAHH). THF, left after CH3•B12 creation, can be converted back into 5,10‐MTHF. 5,10‐MTHF is a carbon donor for the enzyme thymidylate synthase (TS), which catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP); hence, playing a role in de novo DNA synthesis. Upon this reaction, 5,10‐MTFH is converted into dihydrofolate (DHF), which can be reduced by dihydrofolate reductase (DHFR), using NADPH, regenerating THF. B‐family vitamins coming from food indicated in red. Based on Friso et al., 2017 and Green et al., 2017.[ 13 , 15 ]

3. B12 Deficiency

Due to the essential role the vitamin plays, insufficient levels of B12 can be highly detrimental to one's health.[ 19 ] The European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies concluded that the average adult requires a daily intake of 4 µg, and a pregnant woman requires up to 6 µg of B12.[ 35 ] Despite this, individual intake typically consists of 2.4 µg day‐1 of B12, from which approximately 50–60% of the vitamin is absorbed.[ 32 , 36 ] Typically, a healthy individual has a serum level of approximately 200–900 pg mL‐1 (147‐662 pmol L‐1) of B12. A patient is considered deficient when they have less than 200 pg mL‐1 of serum B12, and critically deficient when they have 150 pg mL‐1 (111 pmol L‐1) or less.[ 37 ] However, it should be noted that a B12 deficiency may be difficult to diagnose and the lower limit of B12 serum level may vary.[ 38 ] Also, liver damage, e.g., stemming from alcoholism, as well as systemic low‐grade inflammation, may temporarily allow B12 serum levels to rise due to loss from liver stores, masking real deficiency.[ 39 ]

There are multiple ways to try to assess B12 status. Largely, it is determined through an analysis of total serum B12. However, this method often lacks specificity in the early stages of the deficiency. Due to this, other tests scoring B12 analytes have been developed in order to assess B12 status. When B12 binds to TC it is called holo‐TC.[ 40 ] Some studies observed that the serum holo‐TC concentrations sufficiently reflect B12 status with an increased degree of specificity compared to measuring serum B12 levels. Of note, in plasma, B12 is not only found bound to TC, but to HC as well. In addition, multiple studies that examine the effects of a B12 deficiency also measure homocysteine and MMA concentrations (which will increase because the enzymes converting these compounds need B12 as a co‐factor), to achieve higher accuracy of results, as well.[ 39 ; 41 , 42 , 43 ] In order to strenuously evaluate and assess the possibilities of a B12 deficiency, researchers may thus choose to conduct multiple analyte testing and test for two or more measurements of B12 status simultaneously. An improved indicator of B12 status analysis seems to have been proposed by Fedosov et al. (2015), encompassing combined measurements of serum B12, plasma holo‐TC, homocysteine, and MMA. [ 44 ] Altogether, an accurate diagnosis of this deficiency is necessary to further reveal the presence or absence of correlations between potential clinical manifestations and respective target groups.

4. Vitamin B12 and Carcinogenesis

Carcinomas are cancers derived from epithelial tissue, which make up approximately 80% of all human cancer cases.[ 45 ] Past studies have postulated that there might be a causal relationship between a localized insufficiency of B12 and carcinomas.[ 46 ] In support of this hypothesis, Wu et al. (1999) performed a nested case‐control study and saw that in both menopausal and post‐menopausal breast cancer patients, there were significantly lower concentrations of serum B12, and patients who possessed the lowest B12 had an increased risk of breast cancer.[ 47 ] This inverse association of serum levels of B12 and the risk of cancer is also evident in patients with cervical cancer. Pathak et al. (2014) found that cervical cancer patients had significantly lower serum B12 concentrations when compared to control patients.[ 48 ] Furthermore, there was a significantly higher risk of human papillomavirus (HPV) infection when B12 levels were insufficient. HPV infection has been implicated in the etiology of 70% of cervical cancers. [ 49 ]

This inverse relationship between B12 serum concentration and cancer risk is further seen in cancers of the gastrointestinal tract,[ 50 , 51 ] the liver,[ 33a,b ] the colon, and the rectum.[ 52 , 53 ] An overview of studies into relationships between B12 serum concentrations and cancer risk is given in Table  1 .

Table 1.

Studies highlighting a relationship between B12 and cancer risk

Cancer type Author (Year) Outcome Serum B12 concentration [pg mL‐1]
Breast Wu et al. (1999) [ 47 ]
  • Significantly higher risk of breast cancer

<280
Cervical Pathak et al. (2014) [ 48 ]
  • Significant inverse correlation between homocysteine concentration and B12

  • Lower serum B12 in patients with CIN or cervical cancer

  • Higher risk of HPV infection

(a) 376.54 a)

(b) 341.36

Gastric Murphy et al. (2016) [ 50 ]
  • Significantly increased risk of non‐cardia gastric adenocarcinoma and gastric carcinoid tumors

<200 b)
Miranti et al. (2017)[ 51 ]
  • 5.8‐fold times significantly increased risk of developing non‐cardia gastric adenocarcinoma

  • B12 can serve as a biomarker for atrophic gastritis that precedes non‐cardia gastric adenocarcinoma

<291–300
Hepatic Brunaud et al. (2003) c) [ 33a,b ]
  • Reduced MS activity and DNA methylation

  • Increased risk of hepatocellular carcinoma

<200
Colorectal Dahlin et al. (2008)[ 52 ]
  • Inverse association between plasma B12 levels and risk of rectal cancer

≤221
Sun et al. (2015) [ 53 ]
  • Insignificant reduction in colorectal cancer risk when B12 intake was below 12.8 µg d‐1

  • A slight reduction of colorectal cancer risk with every 4.5 µg d‐1 increment vitamin intake

d)
a)

Median serum B12 concentrations of (a) patients who were diagnosed with CIN while (b) correlates with patients diagnosed with cervical cancer;

b)

All subjects were patients with pernicious anemia;

c)

Animal study with F344 rats;

d)

Average serum B12 concentration not indicated

Certain studies also suggest onco‐protective properties of B12. Zhang et al. (2003) recorded that higher levels of B12 (>572.7 pg mL‐1) were significantly associated with a lower risk of breast cancer amongst premenopausal women.[ 39 ] Similar results were obtained in a cervical cancer study. Piyathilake et al. (2009) reported that sufficient concentrations of B12 (≥200.6 pg mL‐1) correlated with a 50% reduction in cervical intraepithelial neoplasia (CIN) grade 2 diagnosis.[ 54 ] Studies have implicated CIN in the pathogenesis of cervical cancer. In essence, low‐grade lesions (i.e., CIN1) are primarily associated with benign tumors and higher‐grade lesions (i.e., CIN2, CIN3) are associated with highly malignant cervical cancer cases.[ 55 ] Interestingly, women who had low plasma folate concentrations but sufficient concentrations of B12 remained 50% less likely to be diagnosed as CIN2 positive.[ 54 ] This inverse relationship is also apparent with regards to colorectal cancer risk and was further highlighted in a dose‐response meta‐analysis done by Sun et al. (2015). These authors observed a significant relationship between the dietary intake of B12 and colorectal cancer risk. They found a slight reduction in colorectal cancer risk with every 4.5 µg increase in dietary B12 (µg d‐1) intake.[ 53 ] Research by Banjari and Hjartaker (2018) further confirmed this observation.[ 56 ] Last, we should point out that MMA, which increases upon B12 deficiency, seems generally upregulated in serum of the elderly and, as was very recently found, might mediate tumor progression via its induction of SOX4 expression.[ 57 ]

5. Possible Mechanisms

Two possible mechanisms could especially explain the role of B12 in the etiology of some cancers. As previously mentioned, B12 plays a role in the central pathway of the one‐carbon metabolism cycle, which results in the formation of crucial components for the maintenance of DNA synthesis, repair, and methylation. An insufficient amount of B12 could lead to a disruption in this pathway, hence resulting in potentially adverse effects.[ 32 ] When B12 levels are inadequate, MS activity is downregulated, hence impairing the remethylation of homocysteine to methionine. As a result, there is a decrease in methionine and subsequently SAM, as well as a concomitant increase in homocysteine. Such a downregulation of SAM could have detrimental effects for both DNA synthesis and repair, as well as for DNA methylation, possibly explaining some of the findings summarized in Tables 1 and 2.

Table 2.

Studies highlighting correlations between B12 deficiency and aberrant DNA methylation

Cancer type Author (Year) Outcome
Cervical Piyathilake et al. (2014)[ 74 ]
  • Patients with less than 406.58 pg mL‐1 of B12 had less HPV‐16 E 6 promoter methylation

  • 37% chance more likely to develop CIN3

  • A high concentration of serum B12 led to increased methylation of E6 promoter and 60% reduction in risk of being diagnosed with CIN2

  • Weak correlation between serum B12 and folate

Ragasudha et al. (2012)[ 76 ]
  • <160 pm mL‐1 B12 serum concentration led to 14.9 times increased risk of developing CIN1

  • <160 pm mL‐1 B12 serum concentration led to 8.72 times increased risk of developing cervical cancer

  • Dependent on low folate levels

Hepatic Brunaud et al. (2003) [ 33 a‐b]
  • Low B12 activity led to reduced methionine synthase activity

  • Low methionine synthase activity and low B12 led to DNA hypomethylation

  • Livers of rats fed a B12 deficient diet showed methylation patterns similar to animals exposed to chemical carcinogens

Lung Piyathilake et al. (2000)[ 77 ]
  • Localized deficiency of folate and B12 made cells more susceptible to carcinogens present in tobacco smoke

  • Smokers have lower serum B12 levels than non‐smokers

  • B12 levels are lower in squamous cancer cells (3.98 ± 1.3 pg µg‐1 DNA) than in adjacent non‐infected tissue (8.83 ± 1.3 pg µg‐1)

  • Lower DNA methylation in squamous cell cancer cells

  • Decreased activity of MTHR

Johanning et al. (2002)[ 78 ]
  • Lung squamous cell cancer tissues had localized deficiencies of both folate and B12

  • These cells also had global DNA hypomethylation

Colorectal Choi et al. (2004)[ 65 ]
  • Impaired DNA methylation was present in colonic tissue of colorectal cancer cells in rats

  • Supplementation of B12 alleviated the deficiency after 10 weeks

Hasan et al. (2019)[ 23 ]
  • B12 led to increased homocysteine levels

  • Increased homocysteine levels led to an increase of cellular proliferation in Caco‐2 cell lines a)

Head and Neck Colacino et al. (2012)[ 79 ]
  • Individuals with high B12 intake (32 µg d‐1) showed the least amount of tumor suppressor gene methylation

a)

A cell line of human epithelial colorectal adenocarcinoma cells.

5.1. B12 and DNA Synthesis

A deficiency in B12 disrupts deoxythymidine monophosphate (dTMP) biosynthesis, necessary for DNA synthesis, due to the downregulation of essential precursors for dTMP synthesis. Reduced SAM levels, as a result of deficient B12, manifest as a deficiency in THF as the methyl group from 5‐MTHF becomes “trapped”; this model is called the methyl‐trap hypothesis.[ 30 , 58 ] Consequently, this results in a decrease of 5,10‐MTHF, the precursor to 5‐MTHF and the carbon donor for thymidylate synthase (TS); see Figure  4 . TS methylates deoxyuridine monophosphate (dUMP) to become dTMP, which is further phosphorylated to become deoxythymidine triphosphate (dTTP), an essential precursor for DNA synthesis and repair. [ 59 , 60 ] Thus, when the enzyme cannot function properly, it leads to a downregulation of deoxythymidine production and an imbalance in the dUTP/dTTP ratio, which could culminate in an increase of uracil misincorporation in DNA (again, see Figure 4).[ 61 ] When uracil is misincorporated, it results in the recruitment of the enzyme uracil‐DNA glycosylase that can recognize and excise the incorrect base by creating single‐strand or double‐strand breaks (DSBs) in the DNA.[ 62 ] Repair pathways for DSBs are difficult and error‐prone; thus, leading to further complications such as genomic instability, increased mutagenesis, chromosomal breakages, and eventually apoptosis.[ 63 ] All of these enhance an individual's susceptibility to developing cancer.[ 50 ] Hence, deficient B12 levels could lead to a domino effect, culminating in an increased risk of developing cancer.

Figure 4.

Figure 4

The methyl‐trap hypothesis. B12 deficiency impairs MS activity. MS is downregulated and homocysteine cannot be converted to methionine, hence resulting in an increase of homocysteine. This leads to a decrease in SAM production and global hypomethylation. Reduced SAM levels also manifest as a deficiency in THF. This results in a decrease of 5,10‐MTHF, the carbon donor for TS and an accumulation of dUMP, which may lead to increased misincorporation of uracil into DNA strands and halted DNA synthesis. Compare with Figure 3. Green “+” indicates rises in steady state concentrations; Red “–” in general indicates lower steady state concentrations; Based on Choi, 1999 and Lieberman and Marks, 2013.[ 30 , 58 ]

The presence of chromosomal damages was first seen in the form of “Howell‐Jolly bodies” in erythrocytes of patients with megaloblastic anemia, a clinical manifestation of a B12 deficiency.[ 19 ] Other studies (both in vivo and in vitro) have also highlighted the association of low serum B12 with an increase of chromosome damage and micronucleus formation.[ 41 , 64 ] An animal study conducted by Choi et al. (2004) illustrated a causal relationship between a B12 deficiency, anomalies in base substitution, and colorectal carcinogenesis. The study showed that in the colonic mucosa of rats, after 10 weeks of consuming a diet low in B12, there was a 105% increase of uracil incorporation in colonic DNA. In order to establish an independent association, dietary folate and total folate was measured throughout the experiment. No depletion of folate in the colon was evident; thus, supporting the assumption that the base‐insertion anomalies occurred independently of folate levels.[ 65 ]

5.2. Vitamin B12 and DNA Methylation

In addition to effects in DNA synthesis, insufficiency of B12 also leads to aberrant DNA methylation. DNA cytosine methylation is an epigenetic mechanism which involves the transfer of a methyl group to the 5‐carbon position of CpG dinucleotides by DNA methyltransferases (DNMTs), the activity of which is stimulated by SAM. CpG dinucleotides refer to parts of the genome in which a cytosine nucleotide is immediately followed by a guanine nucleotide in the 5’ to 3’ direction.[ 66 ] Chemical exposure and nutritional status have both been implicated in the alteration of methylation patterns.[ 67 ] Broadly speaking, when DNA is hypermethylated, chromatin is compacted and consequently, locally encoded genes are no longer expressed. Conversely, when DNA is hypomethylated, chromatin unravels, and genes can become expressed.[ 13 ] This is particularly dangerous as it could result in the activation of transposable elements,[ 23 ] which are highly mutagenic and have been linked with multiple instances of cancer.[ 68 ] Hence, dysregulation of this process can result in changes in gene expression independent of the primary DNA sequence.[ 13 ] When B12 is lacking, MS is unable to catalyze the conversion of homocysteine to methionine, leading to an upregulation of homocysteine, and subsequently reduced synthesis of SAM (Figure 4). This limits available methyl groups and results in global hypomethylation of DNA, which may result in changes in gene expression. [ 13 , 33 ] Global hypomethylation has been proven to be a risk factor for a variety of cancer types and is commonly seen during early carcinogenesis. [ 69 , 70 , 71 , 72 ]

The causative association of B12, global hypomethylation, and carcinogenesis has been studied extensively with regards to cervical cancer. As stated previously, HPV infection has been heavily implicated in the etiology of cervical cancer. However, it is important to note that only about 10% of all HPV infection cases lead to the development of CIN and only 8% of these cases eventually lead to cervical cancer. The transformative ability of HPV relies heavily on the expression of two viral oncoproteins, E6 and E7. In vitro studies have shown that cervical cancer cells undergo apoptosis when E6 and E7 are not expressed.[ 73 ] According to Huang et al. (2018), B12 and folate work synergistically to maintain the methylation of the HPV E6 promoter and enhancer; thus, blocking the integration of HPV into the host genome.[ 10 ] When B12 is deficient, a decrease in methylation of HPV‐16 E6 promoter and enhancer sites occurs, as reported by Piyathilake et al. (2014).[ 74 ] Of note, HPV‐16 is one of the most frequent causative strains for cervical and anal cancer.[ 75 ] It was observed that patients with less than 406.58 pg mL‐1 of B12 displayed a substantial decrease in HPV‐16 E6 methylation and were 37% more likely to develop CIN3. Inversely, a high concentration of serum B12 led to an increase of methylation of the E6 promoter and a 60% reduction of being diagnosed with CIN2. Again, a weak correlation between serum B12 and serum folate in this experiment also seems to establish that the two nutrients work independently in modulating the methylation of HPV and increasing the risk of CIN.[ 73 ] Similarly, Ragsudha et al. (2011) found that having deficient B12 and folate levels increased the risk of developing CIN1 (about 15‐fold) and cervical cancer (approximately 9‐fold).[ 76 ]

Comparable trends of aberrant methylation have been identified in cases of hepatic, [ 33a,b ] lung, [ 77 , 78 ] colorectal, [ 23 , 65 ] and head and neck cancer (Table  2 ).[ 79 ] Here, it should be pointed out that in this last example the correlation between B12 levels, methylation and cancer risk is not straight forward. In this instance, high B12 intake correlated with lower amounts of local (inactivating) tumor suppressor gene methylation, and thus lower cancer risk.

6. Mitigating and Preventative Treatments

The evidence mentioned, illustrates a possible link between cancer and B12 deficiencies. Thus, we want to highlight possible preventative and mitigating treatments for the deficiency. As an individual's capability of absorbing B12 deteriorates with age, it might be vital to begin preventative measures early.[ 80 ] Here, it must be said that to date, there are no well controlled studies showing that B12 supplements, as such, lower the risk of cancer in general and studies of different cancer types give conflicting results. [ 81 , 82 ] However, extensive comparative studies regarding oncogenesis specifically in vegans are not available either.

To successfully apply early intervention, a diagnostic system for a B12 deficiency is important. Presently, the available on‐demand tests to diagnose the deficiency are serum B12, homocysteine, and MMA blood tests (see above). However, these diagnostic measures are typically only recommended for elderly patients or patients who demonstrate symptoms consistent with a deficiency.[ 12 ] In light of the shifted trend of diet, incorporation of such a diagnostic test in the routine blood analysis for teenagers and young adults, in case they follow a restrictive diet, would in principle allow for effective mitigation and potentially prevent clinical impacts of B12 deficiencies at later (st)ages.

As for preventative measures, there are currently two techniques available to avert a B12 deficiency: supplementation and fortification. With regards to B12 supplementation, there are four routes of administration utilized: oral, nasal, sublingual, and intramuscular.[ 28 ] The United States predominantly utilizes B12 in the form of cyanocobalamin, while hydroxocobalamin is predominantly used in Europe. [ 83 ] Originally, the intramuscular delivery was the preferred method of supplementation for a B12 deficiency, and remains such for clinical B12 deficiencies caused by malabsorption. However, due to the invasive nature of an intramuscular injection, and its dependency on the patient having access to a medical facility, as well as higher costs, this method can lead to low compliance.[ 83 , 84 ]

Currently, oral B12 supplements are the preferred route of B12 supplementation for B12 deficiencies that result from nutritional deficiencies or low consumption. Some studies have found that B12 supplementation via oral administration (whether cyanocobalamin or hydroxocobalamin) had similar efficacies as intramuscular injections.[ 85 , 86 ] However, as these studies were limited in number and quality, doubts regarding the replacement of intramuscular injections linger. A widely cited panel by The Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes (1998) suggests that a small dosage of 5 µg per day of oral cyanocobalamin at a time would be sufficient in ameliorating the deficiency.[ 87 ] Others have suggested that rather a daily oral dosage of 10 µg of B12 is sufficient.[ 4 ] Despite the difference in numbers, supplementation is generally advised for individuals who consume a diet low in B12 and may have a positive impact on public health [ 88 ] and possibly reduce the risk of developing cancer (but see above).[ 61 ]

Although not commonly used, B12 supplements can be administered nasally and sublingually as well. Results from these two administration methods have been positive in ameliorating a B12 deficiency. [ 89 , 90 , 91 ] Despite initial success, more research needs to be done to further test the efficacy and effectiveness of these methods in comparison with that of oral B12 supplements and B12 injections. Furthermore, vegans may choose to consume non‐animal B12 supplements, such as those derived from algae. However, supplements made from algae (e.g., spirulina) have been under debate, and several studies have found that many supplements produced from cyanobacteria can be labeled as “pseudovitamins”, without bioavailability for humans. [ 34 , 92 ] Whether such supplements might further complicate clinical presentations by a residual influence on serum detection and/or unpredictable effects on B12 dependent pathways remains to be seen.

Another method of ensuring adequate intake of B12 for individuals partaking in a vegan diet would be consuming B12 fortified food products. Typically, fortification of food is preferred over oral supplementation due to its cost‐effectiveness.[ 93 ] Currently, no country has implemented a fortification plan for B12,[ 94 ] but products such as nutritional yeast, B12 fortified plant‐based milk, and a variety of meat analogues have been marketed to successfully alleviate a possible B12 deficiency.[ 95 ] In light of the lack of any structural implementation so far, concomitant with the rising percentage of individuals partaking in a vegan diet, concerns have been raised regarding the need for a fortification plan.[ 96 ] One specific problem associated with general fortification of food must be mentioned: for those with specific B12 resorption issues (see above) normal serum B12 levels might mask cellular deficiencies. This does not invalidate the need for fortification, but physicians should be much more acutely aware of this. When, even though serum B12 levels react positively to diet changes, typical neurocognitive symptoms indicating a deficiency persist, B12 might still be the problem. Future development of a robust B12 dependent enzymatic assay with cell extracts might put a stop to such uncertainties.

Different research groups have proposed different vehicles for B12 fortification to see which option would be the most feasible. Winkels et al. (2008) suggested that the implementation of flour co‐fortified with 9.6 µg B12 and 138 µg folic acid would be beneficial in raising serum B12 concentrations and providing necessary dietary requirements. They found that after 12 weeks, the consumption of fortified bread successfully improved serum B12 levels by 49%, decreased homocysteine concentrations by 13%, and MMA concentrations by 10%.[ 97 ] Comparably, Siebert et al. (2017) looked into fortifying toothpaste with B12 for vegans in order to ensure adequate intake of the vitamin and found similar results. In addition to high compliance within groups of participants, the toothpaste was successful in raising both B12 serum concentrations, while simultaneously lowering homocysteine and MMA concentrations.[ 91 ] Further efforts have also been made in fortifying tempeh; a traditional, widely consumed, Indonesian food product made from fermented soybeans.[ 98 ]

7. Limiting Factors and Suggestions for Future Research

It is worth noting that although a B12 deficient diet seems to have carcinogenic effects, there exists contradictory research regarding its onco‐protective nature. Hence, the overconsumption of B12 is not recommended. [ 99 , 100 , 101 ] Some studies have suggested that once a threshold value is reached, a diet high in B12 could potentially lead to carcinogenesis as well. Patients who had greater than 1000 pmol of serum B12 (∼50% above the currently used upper “healthy” limit) had a higher risk of developing solid cancer.[ 102 , 103 ] A potential explanation for these findings could be that higher B12 levels led to the hypermethylation, and subsequently, the silencing of certain key genes (i.e., tumor suppressor genes; but see above). Local hypermethylation of promoter regions in tumor‐suppressor genes, genes involved in cell adhesion or apoptosis, and genes which encode for upstream regulators of essential processes, has been implicated to play a critical role in carcinogenesis.[ 104 ] Hence, in the future, a follow‐up study should be conducted to see whether high B12 consumption past a certain threshold could prove to be cytotoxic and/or carcinogenic. Therefore, a meta‐analysis of the available global data or a large‐scale study to reach a consensus of the threshold level would be useful. Furthermore, relevant underlying molecular processes should be investigated. Here, a first, important but difficult question is of course whether such high levels of B12 are indeed carcinogenic/toxic by themselves, or can, e.g., be understood as markers for excessive food intake (with or without toxic contaminants).

In light of the potential implementation of diagnostic approaches to detect B12 deficiencies, currently the techniques generally used are heavily based on serum B12 levels. However, this is problematic as it was found to be unreliable in diagnosing certain clinical manifestations of a B12 deficiency.[ 12 ] A further improvement of this diagnostic system would be beneficial in accurately mapping deficient patients and developing a potential mitigation strategy.

Another limitation is related to the greatly interconnected role B12 and folate play in the one‐carbon metabolism. Due to this, it is difficult to establish whether B12 works independently in potentially promoting or impeding carcinogenesis, or synergistically with folate. This is of particular interest with regards to a vegan diet, which is high in folate intake, while being deficient in B12.[ 105 ] Additionally, studies have reported that high folate concentration could mask the symptoms of a B12 deficiency; thus, making it harder to diagnose quickly.[ 106 ] Future studies should look into the effects of a diet high in folate and deficient in B12 and whether high folate intake could compensate for the lack of B12 and/or rather mask an existing deficiency.

Moreover, with regards to opportunities for future research, concurrent with the rise of further improved genome editing technology, a potential area of future research would be the application of these innovations to biofortify staple foods of the vegan diet with B12. This might prove to be a challenge as plants are not capable of synthesizing B12 on their own; thus, there would need to be a symbiosis between the staple crop of choice and B12 producing bacteria. [ 107 , 108 ] Tweaking the relevant genes of the microbiome genome may improve B12 levels.

Comprehensive knowledge of the epigenome and its correlation with disease onset, developing a better diagnostic method for B12 deficiency, and establishing further mitigation and prevention strategies, while critically comparing B12 sources, may save some of the future generations of vegans from potentially developing cancer and other major diseases.

8. Conclusion

A growing body of research has shown that insufficient intake of B12 may have a role in carcinogenesis. Evidence indicates that a vegan diet can lead to a B12 deficiency and could possibly inadvertently lead to cancer. This is due to the critical role B12 plays in regulating crucial physiological processes, such as DNA synthesis and DNA methylation. A deficiency in B12 henceforth leads to base‐substitution anomalies and aberrant methylation patterns, leading to genomic instability and abnormal gene expression. Both have been implicated in the development of multiple forms of cancer. Due to the detrimental effects of a B12 deficiency, individuals who partake in a strict vegan diet need to ensure adequate intake through supplementation and/or the consumption of fortified products. However, in light of the existing evidence, the complex correlation between B12 and cancer needs further in‐depth studies. This is in part due to the multifactorial nature of cancer, the role of B12 in MMA conversion, and the interconnected nature of B12 and the other B vitamins.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors thank two anonymous reviewers, whose input really improved the review, making it both more nuanced and more up‐to‐date.

Biographies

Alexandra K. Loedin graduated cum laude from Amsterdam University College in 2020 with a BSc (Hons) Degree, focusing on biomedical science. Writing is one of her passions and her bachelor's thesis was awarded “Thesis of Distinction”. During her studies, she assisted on gene function validation studies of rice traits at IRRI, and after graduating, aided the Indonesian Institute of Science with bioinformatic analyses of toxicity and allergenicity of candidate genes. She also assisted in epidemiological studies on the impact of COVID‐19 for the Indonesian ministry of Economy. Currently, she interns at Ateneo to develop a cost‐efficient diagnostic system for COVID‐19.

graphic file with name MNFR-65-2000945-g007.gif

Dave Speijer studied philosophy, psychology and biochemistry at the University of Amsterdam. After obtaining a master degree cum laude, he got his PhD studying RNA editing in trypanosomes. He works on protein mass spectrometry in clinical settings and is especially interested in molecular evolution, mitochondria, peroxisomes and the evolution of eukaryotes. Another research focus is on the evolution of meiotic sex. He teaches at Amsterdam University Medical Centre (UMC) and Amsterdam University College. He occasionally writes about the connections between science and society in BioEssays.

graphic file with name MNFR-65-2000945-g005.gif

Loedin A. K., Speijer D., Is There a Carcinogenic Risk Attached to Vitamin B12 Deficient Diets and What Should We Do About It? Reviewing the Facts. Mol. Nutr. Food Res. 2021, 65, 2000945. 10.1002/mnfr.202000945

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

  • 1.Merriam‐Webster, vegan. Merriam‐Webster.com, 2020. https://www.merriam‐webster.com/dictionary/vegan
  • 2. Oberst L., Why the Global Rise in Vegan and Plant‐Based Eating Isn't A Fad. Food Revolution Network, 2018.
  • 3. Sebastiani G., Barbero A. H., Borrás‐Novel C., Casanova M. A., Aldecoa‐Bilbao V., Andreu‐Fernández V., Tutusaus M. P., Martínez S. F., Roig M. D. G., García‐Algar O., Nutrients 2019, 11, 557. [Google Scholar]
  • 4.The Vegan Society. Worldwide Statistics Veganism, 2019.
  • 5. Rosell M., Appleby P., Spencer E., Key T., Int J Obes 2006, 30, 1389. [DOI] [PubMed] [Google Scholar]
  • 6. Wang F., Zheng J., Yang B., Jiang J., Fu Y., Li D., J Am Heart Assoc 2015, 4, e002408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Schmidt C. V., Mouritsen O. G., Front. Pscyhol. 2020, 11, 531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Marris E., Nature 2019, 573, 471. [DOI] [PubMed] [Google Scholar]
  • 9. Antony A. C., Am. J. Clin. Nutr. 2003, 78, 3.12816765 [Google Scholar]
  • 10. Huang S. J., Xu Y. M., Lau A. T. Y., Curr Pharmacol Rep 2018, 4, 453. [Google Scholar]
  • 11. Watanabe F., Bito T., Exp Biol Med 2018, 243, 148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Langan R. C., Goodbred A. J., Am. Fam. Physician 2017, 96, 384. [PubMed] [Google Scholar]
  • 13. Friso S., Udali S., De Santis D., Choi S. W., Mol Aspects Med 2017, 54, 28. [DOI] [PubMed] [Google Scholar]
  • 14. Elmadfa I., Singer I., Am. J. Clin. Nutr. 2009, 89, 1693S. [DOI] [PubMed] [Google Scholar]
  • 15. Green R., Allen L. H., A.L.Bjørke‐Monsen, A. B. , Guéant J. L., Miller J. W., Molloy A. M., Nexo E., Stabler S., Toh B. H., Ueland P. M., Yajnik C., Nat. Rev. Dis. Primers 2017, 3, 17040. [DOI] [PubMed] [Google Scholar]
  • 16. R.Pawlak, S. E. L. , Babatunde T., Eur J Clin Nutr 2014, 68, 541. [DOI] [PubMed] [Google Scholar]
  • 17. Haddad E. H., Jaceldo‐Siegl K., Oda K., Fraser G. E., Curr Dev Nutr 2020, 4, nzaa008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Allen L. H., Am J Clin Nutri 2009, 89, 693S. [DOI] [PubMed] [Google Scholar]
  • 19. Wolffenbuttel B. H. R., Wouters H. J. C. M., Heiner‐Fokkema M. R., van der Klauw M. M., Mayo Clin Proc Innov Qual Outcomes 2019, 3, 200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Pawlak R., Parrott S. J., Raj S., Cullum‐Dugan D., Lucus D., Nutr Rev 2013, 71, 110. [DOI] [PubMed] [Google Scholar]
  • 21. Kulkarni A., K.Dangat, A. K. , Sable P., Chavan‐Gautam P., Joshi S., PLoS One 2011, 6, e17706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Finkelstein J. L., Layden A. J., Stover P. J., Adv Nutri 2015, 6, 552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Hasan T., Arora R., Bansal A. K., Bhattacharya R., Sharma G. S., Singh L. R., Exp. Mol. Med. 2019, 51, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Tinelli C., Di Pino A., Ficulle E., Marcelli S., Feligioni M., Front Nutr. 2019, 6, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Dagenais G. R., Leong D. P., Rangarajan S., Lanas F., Lopez‐Jaramillo P., Gupta R., Diaz R., Avezum A., Oliveira G. B. F., Wielgosz A., Parambath S. R., Mony P., Alhabib K. F., Temizhan A., Ismail N., Chifamba J., Yeates K., Khatib R., Rahman O., Zatonska K., Kazmi K., Wei L., Zhu J., Rosengren A., Vijayakumar K., Kaur M., Mohan V., Yusufali A., Kelishadi R., Teo K. K., Joseph P., Yusuf S., Lancet 2020, 395, 785. [DOI] [PubMed] [Google Scholar]
  • 26. Tefferi A., Pruthi R. K., Mayo Clin Proc 1994, 69, 181. [DOI] [PubMed] [Google Scholar]
  • 27. Jägerstad M., Arkbåge K., COBALAMINS | Properties and Determination in Encyclopedia of Food Sciences and Nutrition, Vol. 2 (Ed: Caballero B.), Academic Press, Oxford: 2003, pp. 1419–1427. [Google Scholar]
  • 28. Engelking L. R., Cobalamin (B12) in Textbook of Veterinary Physiological Chemistry, Vol. 3 (Ed: Engelking L.R.), Academic Press, Boston: 2015, Ch. 43. [Google Scholar]
  • 29. Moll R., Davis B., Med (Baltimore) 2017, 45, 198. [Google Scholar]
  • 30. Lieberman M., Marks A. D., Marks’ Basic Medical Biochemistry: a Clinical Approach, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA: 2013. [Google Scholar]
  • 31. Shipton M. J., Thachil J., Clin Med 2015, 15, 145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Antony A. C., Megaloblastic Anemias in Hematology: Basic Principles and Practice, Vol. 7 (Eds: Hoffman R., Benz E., Heslop H., Weitz) J., Churchill Livingstone‐Elsevier, Philadelphia, PA: 2018, Ch. 39. [Google Scholar]
  • 33.a) Brunaud L., Alberto J. M., Ayav A., Gérard P., Namour F., Antunes L., Braun M., Bronowicki J. P., Bresler L., Guéant J. L., Clin. Chem. Lab. Med. 2003, 41, 1012; [DOI] [PubMed] [Google Scholar]; b) </number>Brunaud L., Alberto J. M., Ayav A., Gérard P., Namour F., Antunes L., Braun M., Bronowicki J. P., Bresler L., Guéant J. L., Digestion 2003, 68, 133. [DOI] [PubMed] [Google Scholar]
  • 34. Rizzo G., Laganà A. S., Rapisarda A. M. C., La Ferrera G. M. G., Buscema M., Rossetti P., Nigro A., Muscia V., Valenti G., Sapia F., Sarpietro G., Zigarelli M., Vitale S. G., Nutrients 2016, 8, 767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. European Food Safety Authority , EFSA J. 2015, 13, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Hanna S., Lachover L., Rajarethinam R. P., Prim Care Companion J Clin Psychiatry 2009, 11, 269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Vashi P., Edwin P., Popiel B., Lammersfeld C., Gupta D., PLoS One 2016, 11, e0147843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Pott J. W. R., Acta Ophthalmologica 2014, 92, e76. [DOI] [PubMed] [Google Scholar]
  • 39. Zhang S. M., Willett W. C., Selhub J., Hunter D. J., Giovannucci E. L., Holmes M. D., Colditz G. A., Hankinson S. E., J Natl Cancer Inst 2003, 95, 373. [DOI] [PubMed] [Google Scholar]
  • 40. Green R., Miller J. W., in Handbook of Vitamins, 5th ed. (Eds: Zempleni J., Suttie J. W., Gregory J. F. III, Stover P. J.), CRC Press, Boca Raton, FL: 2013, Ch. 12. [Google Scholar]
  • 41. Fenech M., Mutat Res 2012, 733, 21. [DOI] [PubMed] [Google Scholar]
  • 42. Yadav M. K., Manoli N. M., Madhunapantula S. V., PLoS One 2016, 11, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Yadav M. K., Manoli N. M., Vimalraj S., Madhunapantula S. R., Int. J. Biol. Macromol. 2018, 21, 179. [DOI] [PubMed] [Google Scholar]
  • 44. Fedosov S. N., Brito A., Miller J. W., Green R., Allen L. H., Clin. Chem. Lab. Med. 2015, 53, 1215. [DOI] [PubMed] [Google Scholar]
  • 45. Rogalla S., Contag C. H., Cancer J. 2015, 21, 179. [DOI] [PubMed] [Google Scholar]
  • 46. Piyathilake C. J., Macaluso M., Hine R. J., Vinter D. W., Richards E. W., Krumdieck C. L., Cancer Epidemiol Biomarkers Prev 1995, 4, 751. [PubMed] [Google Scholar]
  • 47. Wu K., Helzlsouer K. J., Comstock G. W., Hoffman S. C., Nadeau MR M. R., Selhub J., Cancer Epidemiol Biomarkers Prev 1999, 8, 209. [PubMed] [Google Scholar]
  • 48. Pathak S., Bajpai D., Banerjee A., Bhatla N., Jain S. K., Jayaram H. N., Singh N., Nutr Cancer 2014, 66, 818. [DOI] [PubMed] [Google Scholar]
  • 49. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D. M., Piñeros M., Znaor A., Bray F., Int. J. Cancer 2019, 144, 1941. [DOI] [PubMed] [Google Scholar]
  • 50. Murphy G., Dawsey S. M., Engels E. A., Ricker W., Parsons R., Etemadi A., Lin S. W., Abnet C. C., Freedman N. D., Clin. Gastroenterol. Hepatol. 2015, 13, 2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Miranti E. H., Stolzenberg‐Solomon R., Weinstein S. J., Selhub J., Männistö S., Taylor P. R., Freedman N. D., Albanes D., Abnet C. C., Murphy G., Int. J. Cancer 2017, 141, 1120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Dahlin A. M., van Guelpen B., Hultdin J., Johansson I., Hallmans G., Palmqvist R., Int. J. Cancer 2008, 122, 2057. [DOI] [PubMed] [Google Scholar]
  • 53. Sun N. H., Huang X. Z., Wang S. B., Li Y., Wang L. Y., Wang H. C., Zhang C. W., Zhang C., Liu H. P., Wang Z. N., Public Health Nutr 2016, 19, 1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Piyathilake C. J., Macaluso M., Alvarez R. D., Bell W. C., Heimburger D. C., Partridge E. E., Cancer Prev. Res. 2009, 2, 658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Holly E. A., Annu Rev Public Health 1996, 17, 69. [DOI] [PubMed] [Google Scholar]
  • 56. Banjari I., Hjårtaker A., Med Hypotheses 2018, 116, 105. [DOI] [PubMed] [Google Scholar]
  • 57. Gomes A. P., D.Ilter, V. L. , Endress J. E., Fernández‐Garcia J., Rosenzweigh A., Schild T., Broekaert D., Ahmed A., Planque M., Elia I., Han J., Kinzig C., Mullarky E., Mutvei A. P., Asara J., de Cabo R., Cantley L. C., Dephoure N., Fendt S., Blenis J., Nature 2020, 585, 283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Choi S., Nutr Rev 1999, 57, 250. [DOI] [PubMed] [Google Scholar]
  • 59. Chu E., Gollerkeri A., Resistance to Inhibitor Compounds of Thymidylate Synthase in Encyclopedia of Cancer, 2nd ed., Vol. 4 (Ed: Bertino J.R.), Academic Press, 2002, p. 107. [Google Scholar]
  • 60. Nygaard P., Saxild H. H., Nucleotide Metabolism in Encyclopedia of Microbiology, Vol. 3 (Ed: Schaechter M.), Academic Press, 2009, p. 296. [Google Scholar]
  • 61. Ames B. N., Wakimoto P., Nat. Rev. Cancer 2002, 2, 694. [DOI] [PubMed] [Google Scholar]
  • 62. Andersen S., Heine T., Sneve R., König I., Krokan H. E., Epe B., Nilsen H., Carcinogenesis 2005, 26, 547. [DOI] [PubMed] [Google Scholar]
  • 63. Scully R., Panday A., Elango R., Willis N. A., Nat. Rev. Mol. Cell Biol. 2019, 20, 698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Contestabile R., di Salvo M. L., Bunik V., Tramonti A., Vernì F., Open Biol 2020, 10, 200034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Choi S. W., Friso S., Ghandour H., Bagley P. J., Selhub J., Mason J. B., J. Nutr. 2004, 134, 750. [DOI] [PubMed] [Google Scholar]
  • 66. Serrano M., Epigenetic Cerebellar Diseases in Handbook of Clinical Neurology, Vol. 155 (Eds: Manto M., Huisman T.A.G.M.), Elsevier, 2018, Ch. 15. [DOI] [PubMed] [Google Scholar]
  • 67. Martin E. M., Fry R. C., Annu Rev Public Health 2018, 39, 309. [DOI] [PubMed] [Google Scholar]
  • 68. Anwar S. L., Wulaningsih W., Lehmann U., Int. J. Mol. Sci. 2017, 18, 974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Feinberg A. P., Vogelstein B., Nature 1983, 301, 89. [DOI] [PubMed] [Google Scholar]
  • 70. Gama‐Sosa M. A., Slagel V. A., Trewiyn R. W., Oxehandler R., Kuo K. C., Gehrke C. W., Ehrlich M., Nucleic Acids Res. 1983, 11, 6683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Toraño E. G., Petrus S., Fernandez A. F., Fraga M. F., Clin. Chem. Lab. Med. 2012, 50, 1733. [DOI] [PubMed] [Google Scholar]
  • 72. Jiménez‐Wences H., Peralta‐Zaragoza O., Fernández‐Tilapa G., Oncol Rep 2014, 31, 2467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Pal A., Kundu R., Front Microbiol 2020, 10, 3116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Piyathilake C. J., Macaluso M., Chambers M. M., Badiga S., Siddiqui N. R., Bell W. C., Edberg J. C., Partridge E. E., Alvarez R. D., Johanning G. L., Cancer Prev. Res. 2014, 7, 1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Yim E. K., Park J. S., Cancer Res. Treat. 2005, 37, 319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Ragasudha P. N., Thulaseedharan J. V., Wesley R., Jayaprakash P. G., Lalitha P., Pillai M. R., Nutr Cancer 2012, 64, 550. [DOI] [PubMed] [Google Scholar]
  • 77. Piyathilake C. J., Johanning G. L., Macaluso M., Whiteside M., Oelschlager D. K., Heimburger D. C., Grizzle W. E., Nutr Cancer 2000, 37, 99. [DOI] [PubMed] [Google Scholar]
  • 78. Johanning G. L., Heimburger D. C., Piyathilake C. J., Cancer J Nutr 2002, 132, 3814S. [DOI] [PubMed] [Google Scholar]
  • 79. Colacino J. A., Arthur A. E., Dolinoy D. C., Sartor M. A., S.A.Duffy, D. B. C. , Bradford C. R., Walline H. M., McHugh J. B., Silva N. D., Carey T. E., Wolf G. T., Taylor J. M. G., Peterson K. E., Rozek L. S., Epigenetics 2012, 7, 883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Stover P. J., Curr. Opin. Clin. Nutr. Metab. Care 2016, 176, 139. [Google Scholar]
  • 81. Wei D., Mao Q., Nutr J 2020, 19, 111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Zeng J., Gu Y., Fu H., Liu C., Zou Y., Chang H., Clin. Breast Cancer 2020, 20, e469. [DOI] [PubMed] [Google Scholar]
  • 83. Ahangar E. R., Annamaraju P., Hydroxocobalamin, StatPearls Publishing, Treasure Island, FL: 2020. [Google Scholar]
  • 84. Bahadir A., Reis P. G., Erduran E., J Paediatr Child Health 2014, 50, 721. [DOI] [PubMed] [Google Scholar]
  • 85. Schijns W., Horman J., van der Meer L., Janssen I. M., van Laarhoven C. J., Berends F. J., Aarts E. O., Am. J. Clin. Nutr. 2018, 108, 6. [DOI] [PubMed] [Google Scholar]
  • 86. Sanz‐Cuesta T., Escortell‐Mayor E., Cura‐Gonzalez I., Martin‐Fernandez J., Riesgo‐Fuertes R., Garrido‐Elustondo S., Mariño‐Suárez J. E., Àlvarez‐Villalba M., Gómez‐Gascón T., González‐Garcia I., González‐Escobar P., Cabañero C. V. M., Noguerol‐Álvarez M., de Blas‐González F. G., Baños‐Morras R., Díaz‐Laso C., Caballero‐Ramírez N., de‐Dios A. H., Fernández‐García R., Herrero‐Hernández J., Pose‐García B., Sevillano‐Palmero M. L., Mateo‐Ruiz C., Medina‐Bustillo B., Aguilar‐Jiménez M., BMJ Open 2020, 10, e033687. [Google Scholar]
  • 87. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate , Other B Vitamins and C, National Academies Press, Washington, DC: 1998. [Google Scholar]
  • 88. Wolffenbuttel B. H. R., Heiner‐Fokkema M. R., Green R., Gans R. O. B., BMC Med. 2020, 18, 307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Sharabi A., Cohen E., Sulkes J., Garty M., Br. J. Clin. Pharmacol. 2003, 56, 635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Slot W., Merkus F., van Deventer S., Tytgat G., Gastroenterology 1997, 113, 430. [DOI] [PubMed] [Google Scholar]
  • 91. Siebert A. K., Obeid R., Weder S., Awwad H. M., Sputtek A., Geisel J., Keller M., Am. J. Clin. Nutr. 2017, 105, 618. [DOI] [PubMed] [Google Scholar]
  • 92. Helliwell K. E., Lawrence A. D., Holzer A., Kudahl U. J., Sasso S., Kräutler B., Scanlan D. J., Warren M. J., Smith A. G., Curr. Biol. 2016, 26, 999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. de Benoist B., Food Nutr Bull 2008, 29, S238. [DOI] [PubMed] [Google Scholar]
  • 94. Carmel R., Food Nutr Bull 2008, 29, S177. [DOI] [PubMed] [Google Scholar]
  • 95. Mangels R., Simply Vegan, 5th ed., Vegetarian Resource Group U.S, Baltimore, MD: 2013. [Google Scholar]
  • 96. Green R., Am. J. Clin. Nutr. 2009, 89, 712S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Winkels R. M., Brouwer I. A., Clarke R., Katan M. B., Verhoef P., Am. J. Clin. Nutr. 2008, 88, 348. [DOI] [PubMed] [Google Scholar]
  • 98. Wolkers–Rooijackers J. C. M., Endika M. F., Smid E. J., LWT. 2018, 96, 513. [Google Scholar]
  • 99. Mokarram P., Naghibalhossaini F., Firoozi M. S., Hosseini S. V., Izadpanah A., Salahi H., Malek‐Hosseini S. A., Talei A., Mojallal M., World J. Gastroenterol. 2008, 14, 3662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Xiao Q., Freedman N. D., Ren J., Hollenbeck A. R., Abnet C. C., Park Y., Br. J. Cancer 2014, 110, 1328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Arendt J. F. H., Farkas D. K., Pedersen L., Nexo E., Sørensen H. T., Cancer Epidemiol 2016, 40, 158. [DOI] [PubMed] [Google Scholar]
  • 102. Urbanski G., Hamel J. F., Prouveur B., Annweiler C., Ghali A., Cassereau J., Lozac'h P., Lavigne C., Lacombe V., J Clin Med 2020, 9, 474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Fanidi A., Carreras‐Torres R., Larose T. L., Yuan J. M., Stevens V. L., Weinstein S. J., Albanes D., Prentice R., Pettinger M., Cai Q., Blot W. J., Arslan A. A., Zeleniuch‐ Jacquotte A., McCullough M. L., Le Marchand L., Wilkens L. R., Haiman C. A., Zhang X., Stampfer M. J., Smith‐Warner S. A., Giovannucci E., Giles G. G., Hodge A. M., Severi G., Johansson M., Grankvist K., Langhammer A., Brumpton B. M., R.Wang, Y. T. G. , Ericson U., Bojesen S. E., Arnold S. M., Koh W. P., Shu X. O., Xiang Y. B., Li H., Zheng W., Lan Q., Visvanathan K., Hoffman‐Bolton J., Ueland P. M., Midttun Ø., Caporaso N. E., Purdue M., Freedman N. D., Buring J. E., Lee I. M., Sesso H. D., Gaziano J. M., Manjer J., Relton C. L., Hung R. J., Amos C. I., Johansson M., Brennan P., Int. J. Cancer 2019, 145, 1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Kulis M., Esteller M., Adv. Genet. 2010, 70, 27. [DOI] [PubMed] [Google Scholar]
  • 105. Bar‐Sella P., Rakover Y., Ratner D., Isr. J. Med. Sci. 1990, 26, 309. [PubMed] [Google Scholar]
  • 106. Titcomb T. J., Tanumihardjo S. A., Compr Rev Food Sci Food Saf 2019, 18, 1968. [DOI] [PubMed] [Google Scholar]
  • 107. Blancquaert D., De Steur H., Gellynck X., van Der Straeten D., J. Exp. Bot. 2014, 65, 895. [DOI] [PubMed] [Google Scholar]
  • 108. Fang H., Kang J., Zhang D., Microb. Cell Fact. 2017, 16, 15. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.


Articles from Molecular Nutrition & Food Research are provided here courtesy of Wiley

RESOURCES